Tyrosine ( DrugBank: Tyrosine )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3
86	肺動脈性肺高血圧症	6
111	先天性ミオパチー	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03655236 (ClinicalTrials.gov)	February 18, 2019	18/8/2018	PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of ...	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkin ...	Early Parkinson Disease	Drug: K0706;Other: placebo	Sun Pharma Advanced Research Company Limited	NULL	Recruiting	50 Years	N/A	All	504	Phase 2	United States;Hungary;India;Poland;Slovakia;Spain
2	NCT02259049 (ClinicalTrials.gov)	October 2014	3/10/2014	The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease	The Effects of L-Tyrosineon Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Park ...	Blood Pressure	Dietary Supplement: L-tyrosine;Dietary Supplement: Sugar Pill	New York Institute of Technology	NULL	Completed	40 Years	84 Years	Both	6	Phase 0	United States
3	NCT01676103 (ClinicalTrials.gov)	September 2012	28/8/2012	The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease	The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease	Parkinson's Disease	Dietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar Pill	New York Institute of Technology	Michael J. Fox Foundation for Parkinson's Research	Completed	50 Years	80 Years	Both	40	Phase 1/Phase 2	United States

First Previous1Next Last

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000001709	2009/02/01	16/02/2009	Multikinase Inhibitor (Tyrosineand Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pu ...	Multikinase Inhibitor (Tyrosineand Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pu ...	pulmonary arterial hypertension	administration of sorafenib, which is the multikinase inhibitor (tyrosineand serine/threonine kinase ...	Medical Education Center, School of Medicine, Keio University	NULL	Pending	20years-old	Not applicable	Male and Female	10	Not selected	Japan
2	JPRN-UMIN000001578	2008/12/01	16/12/2008	Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension	TyrosineKinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension - TyrosineKinas ...	pulmonary arterial hypertension	administration of tyrosine kinase inhibitor (imatinib)	Medical Education Center	NULL		20years-old	Not applicable	Male and Female	10	Not selected	Japan
3	EUCTR2005-005569-12-AT (EUCTR)	11/08/2006	13/07/2006	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six mont ...	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six mont ...	pulmonary arterial hypertension	Product Name: Glivec Product Code: STI571 INN or Proposed INN: Imatinib	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes			Austria;Germany;United Kingdom
4	EUCTR2005-005569-12-DE (EUCTR)	24/05/2006	27/03/2006	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six mont ...	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six mont ...	pulmonary arterial hypertension	Trade Name: Glivec 100 mg Hartkapsel Product Name: Glivec Product Code: STI571 INN or Proposed INN: Ima ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60		Austria;Germany;United Kingdom
5	NCT00477269 (ClinicalTrials.gov)	April 2006	22/5/2007	Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six ...	Pulmonary Arterial Hypertension	Drug: Imatinib mesylate;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	59	Phase 2/Phase 3	United States;Austria;Germany;United Kingdom
6	EUCTR2005-005569-12-GB (EUCTR)	26/01/2006	02/12/2005	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six mont ...	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six mont ...	pulmonary arterial hypertension	Trade Name: Glivec Product Name: Glivec Product Code: STI571 INN or Proposed INN: Imatinib Product Code: ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60		Austria;Germany;United Kingdom

First Previous1Next Last

先頭へ

111. 先天性ミオパチー

臨床試験数 : 10 / 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 9

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02035501 (ClinicalTrials.gov)	January 2014	2/7/2013	Treatment of TNNT1-Myopathy With L-Tyrosine.	Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial.	Nemaline Myopathy	Drug: L-Tyrosine;Drug: Placebo	Hadassah Medical Organization	NULL	Enrolling by invitation	N/A	20 Years	Both	10	Phase 2	Israel

First Previous1Next Last

先頭へ